[go: up one dir, main page]

MX342423B - Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio. - Google Patents

Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.

Info

Publication number
MX342423B
MX342423B MX2012010021A MX2012010021A MX342423B MX 342423 B MX342423 B MX 342423B MX 2012010021 A MX2012010021 A MX 2012010021A MX 2012010021 A MX2012010021 A MX 2012010021A MX 342423 B MX342423 B MX 342423B
Authority
MX
Mexico
Prior art keywords
sulfurterahydropyran
cotrans
porters
benzylphenyl
inhibitors
Prior art date
Application number
MX2012010021A
Other languages
English (en)
Other versions
MX2012010021A (es
Inventor
Manton Brown Philip
Philip Freiman Joel
Reed Powell David
Original Assignee
Lexicon Pharmaceuticals Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc * filed Critical Lexicon Pharmaceuticals Inc *
Publication of MX2012010021A publication Critical patent/MX2012010021A/es
Publication of MX342423B publication Critical patent/MX342423B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se refiere a métodos para mejorar la salud cardiovascular y/o salud metabólica de pacientes, particularmente los que padecen diabetes tipo 2, , así como compuestos y composiciones farmacéuticas útiles para ello.
MX2012010021A 2010-03-02 2011-03-01 Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio. MX342423B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30959210P 2010-03-02 2010-03-02
PCT/US2011/026591 WO2011109333A1 (en) 2010-03-02 2011-03-01 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients

Publications (2)

Publication Number Publication Date
MX2012010021A MX2012010021A (es) 2012-09-21
MX342423B true MX342423B (es) 2016-09-28

Family

ID=43795398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010021A MX342423B (es) 2010-03-02 2011-03-01 Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.

Country Status (24)

Country Link
US (3) US20110218159A1 (es)
EP (1) EP2542236B1 (es)
JP (2) JP6126383B2 (es)
KR (2) KR20130026422A (es)
CN (1) CN102821764A (es)
AR (1) AR080444A1 (es)
AU (1) AU2011223861B2 (es)
BR (1) BR112012021771B1 (es)
CA (1) CA2791300C (es)
CY (1) CY1118611T1 (es)
DK (1) DK2542236T3 (es)
ES (1) ES2609104T3 (es)
HR (1) HRP20170093T1 (es)
HU (1) HUE031441T2 (es)
IL (1) IL221372A0 (es)
LT (1) LT2542236T (es)
MX (1) MX342423B (es)
PL (1) PL2542236T3 (es)
PT (1) PT2542236T (es)
RS (1) RS55620B1 (es)
RU (1) RU2012141893A (es)
SI (1) SI2542236T1 (es)
TW (1) TWI562775B (es)
WO (1) WO2011109333A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
DK2925735T3 (da) 2012-11-20 2019-06-17 Lexicon Pharmaceuticals Inc Inhibitorer for natriumglucose-cotransporter 1
US20140371243A1 (en) * 2013-06-14 2014-12-18 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
WO2014206349A1 (zh) * 2013-06-28 2014-12-31 四川海思科制药有限公司 氧杂-硫杂-双环[3.2.1]辛烷衍生物、制备方法及其用途
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
EP3466958B1 (en) * 2016-05-25 2020-04-29 Crystal Pharmaceutical (Suzhou) Co., Ltd. New crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110066302B (zh) 2018-01-23 2022-12-27 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
WO2019149178A1 (zh) 2018-01-31 2019-08-08 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
BR112020019624A8 (pt) * 2018-03-28 2022-03-03 Avolynt Método para tratar a hipoglicemia pós-prandial
CN110092768A (zh) * 2018-04-23 2019-08-06 中国科学院成都生物研究所 包含钠-葡萄糖协同转运蛋白1抑制剂的组合物及使用方法
CN110117300A (zh) * 2018-04-23 2019-08-13 中国科学院成都生物研究所 包含钠-葡萄糖协同转运蛋白1抑制剂的药物用途
CN108610385A (zh) * 2018-04-23 2018-10-02 中国科学院成都生物研究所 一种钠-葡萄糖协同转运蛋白1抑制剂的药物用途
CN110117304A (zh) * 2018-04-23 2019-08-13 中国科学院成都生物研究所 一种钠-葡萄糖协同转运蛋白1和2抑制剂的药物用途
JP2022502393A (ja) * 2018-09-26 2022-01-11 レクシコン ファーマシューティカルズ インコーポレイテッド Ｎ−（１−（（２−（ジメチルアミノ）エチル）アミノ）−２−メチル−１−オキソプロパン−２−イル）−４−（４−（２−メチル−５−（（２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−３，４，５−トリヒドロキシ−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−２−イル）ベンジル）フェニル）ブタンアミドの結晶形態及びそれらの合成方法
EP3997079A4 (en) 2019-07-10 2023-03-01 Sunshine Lake Pharma Co., Ltd. GLUCOPYRANOSYL DERIVATIVES AND THEIR USES
EP4026564A4 (en) * 2019-09-04 2023-03-15 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC PROCEDURE FOR DIABETES USING COMBINATION MEDICATION
EP4249479A4 (en) * 2020-11-19 2024-12-18 Beijing Increase Innovative Drug Co., Ltd. GLUCOSIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS APPLICATION

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (es) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
ATE60571T1 (de) 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
IE63760B1 (en) 1987-05-22 1995-06-14 Squibb & Sons Inc Phosphorus-containing HMG-CoA reductase inhibitors
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5712396A (en) 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
DE69324504T2 (de) 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
ATE344279T1 (de) 1995-12-13 2006-11-15 Univ California Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
WO1999038501A2 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
AU3034299A (en) 1998-03-09 1999-09-27 Fondatech Benelux N.V. Serine peptidase modulators
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
SK18822000A3 (sk) 1998-07-06 2001-12-03 Bristol-Myers Squibb Company Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
MXPA04003553A (es) 2001-10-18 2004-07-22 Bristol Myers Squibb Co Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
BRPI0813840A2 (pt) * 2007-07-26 2017-06-06 Lexicon Pharmaceuticals Inc métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio
PE20090603A1 (es) * 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
CL2008003653A1 (es) * 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Also Published As

Publication number Publication date
JP2013521293A (ja) 2013-06-10
EP2542236B1 (en) 2016-10-26
PL2542236T3 (pl) 2017-05-31
AU2011223861A1 (en) 2012-08-23
ES2609104T3 (es) 2017-04-18
PT2542236T (pt) 2017-02-06
HUE031441T2 (hu) 2017-07-28
DK2542236T3 (en) 2017-01-30
LT2542236T (lt) 2017-03-27
US20140018308A1 (en) 2014-01-16
EP2542236A1 (en) 2013-01-09
IL221372A0 (en) 2012-10-31
RS55620B1 (sr) 2017-06-30
US20110218159A1 (en) 2011-09-08
BR112012021771A2 (pt) 2017-07-04
JP2017081982A (ja) 2017-05-18
KR20180051683A (ko) 2018-05-16
CN102821764A (zh) 2012-12-12
TW201130486A (en) 2011-09-16
CA2791300C (en) 2019-02-19
BR112012021771B1 (pt) 2019-06-11
JP6126383B2 (ja) 2017-05-10
AR080444A1 (es) 2012-04-11
CA2791300A1 (en) 2011-09-09
RU2012141893A (ru) 2014-04-10
KR20130026422A (ko) 2013-03-13
TWI562775B (en) 2016-12-21
WO2011109333A1 (en) 2011-09-09
CY1118611T1 (el) 2017-07-12
AU2011223861B2 (en) 2015-07-23
MX2012010021A (es) 2012-09-21
SI2542236T1 (sl) 2017-02-28
HRP20170093T1 (hr) 2017-03-24
US20160022718A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
MX342423B (es) Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
IN2012DN01233A (es)
MY162146A (en) Pharmaceutical composition
MX2009010894A (es) Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
WO2011082266A3 (en) Substituted heterocyclic compounds
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
MY155695A (en) Quinoxalinedione derivatives
MX2009012920A (es) Compuestos heptaciclicos y usos farmaceuticos de los mismos para la prevencion y tratamiento de diabetes y sindrome metabolico.
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
MX342947B (es) Tratamiento de diabetes tipo 2.
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds
GB0615105D0 (en) Novel compounds
WO2011156820A9 (en) Compositions, methods and uses for treatment of type 1 diabetes
WO2011127482A3 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES

Legal Events

Date Code Title Description
FG Grant or registration